Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that is extremely challenging not only for diagnosed individuals, but also for their families and the wider healthcare system.
Due to rapid onset and progression of symptoms, early detection and effective management are both critical. Some early signs of ALS may include muscle cramps in the arm, leg, shoulder or tongue, trouble walking, tripping and falling, weakness in the legs, arm or neck, slurred and nasal speech, and tight and stiff muscles (spasticity). Later, ALS symptoms may include trouble chewing food and swallowing (dysphagia), unintentional loss of saliva from the mouth (drooling or sialorrhoea), trouble speaking or forming words, unintended crying, laughing or other emotional displays, constipation and trouble breathing (dyspnoea).
In advanced stages, people with ALS may lose the ability to stand, walk, independently get in and out of bed, use their hands and arms, or breathe without assistance. Since they typically retain the capacity to reason, remember and understand, they are aware of their gradual loss of function.
Although scientists are yet to develop a cure, recent technological advancements have made significant progress in the management of this complex disease. These innovations not only aim to enhance early diagnosis but also significantly improve quality of life and provide more effective, personalised treatments.
AI and machine learning for early ALS detection
Advances in AI algorithms have allowed for the analysis of complex medical data, such as neuroimaging and genetic profiling, to aid the early identification of ALS biomarkers. AI technology can streamline the detection process by using machine learning models to process vast data sets and identify patterns that are not immediately visible to the human eye.
In addition, AI tools are being developed to monitor changes in speech patterns – often one of the earliest symptomatic signs of ALS – representing yet another instance where AI can help detect changes and support earlier diagnoses. Using deep learning to assess voice and speech dynamics, it is possible to detect early motor neuron damage before more advanced symptoms appear.
Next to detection, machine learning techniques are being used to analyse patient data and create predictive models that forecast disease progression. This can enable clinicians to create more personalised treatment plans and help the biopharma industry to more effectively build clinical trial designs. The ability to forecast a disease’s trajectory is crucial to allow for more targeted therapies and earlier inventions, with the aim of slowing down disease progression and improving patient outcomes.
Read the article in full here.